Cefpiramide |
|
| AHFS/Drugs.com | International Drug Names |
|---|
Routes of administration | Intravenous, intramuscular |
|---|
| ATC code | |
|---|
|
| Protein binding | 93% to 99.3% |
|---|
| Elimination half-life | 4.44 hours |
|---|
| Excretion | Renal and fecal |
|---|
|
(6R)-7-{[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl- 4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino}- 3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo- 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| DrugBank | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| KEGG | |
|---|
| ChEBI | |
|---|
| ChEMBL | |
|---|
| CompTox Dashboard (EPA) | |
|---|
|
| Formula | C25H24N8O7S2 |
|---|
| Molar mass | 612.64 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
| Melting point | 213 to 215 °C (415 to 419 °F) (dec.) |
|---|
O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)[C@@H](c3ccc(O)cc3)NC(=O)C\4=C\N\C(=C/C/4=O)C)CSc5nnnn5C)C(=O)O
|
InChI=1S/C25H24N8O7S2/c1-11-7-16(35)15(8-26-11)20(36)27-17(12-3-5-14(34)6-4-12)21(37)28-18-22(38)33-19(24(39)40)13(9-41-23(18)33)10-42-25-29-30-31-32(25)2/h3-8,17-18,23,34H,9-10H2,1-2H3,(H,26,35)(H,27,36)(H,28,37)(H,39,40)/t17-,18-,23-/m1/s1 YKey:PWAUCHMQEXVFJR-PMAPCBKXSA-N Y
|
N Y (what is this?) (verify) |
Cefpiramide is a third-generation cephalosporin antibiotic.
References
External links
- Wang H, Yu Y, Xie X, Wang C, Zhang Y, Yuan Y, Zhang X, Liu J, Wang P, Chen M (2000). "In-vitro antibacterial activities of cefpiramide and other broad-spectrum antibiotics against 440 clinical isolates in China". J Infect Chemother. 6 (2): 81–85. doi:10.1007/PL00012156. PMID 11810540. S2CID 30532462.
- Iakovlev V, Vishnevskiĭ V, Khlebnikov E, Khadin I, Plavlova M, Elagina L, Izotova G (1995). "[Cefpiramide (Tamicin) in the treatment of purulent complications of abdominal surgery]". Antibiot Khimioter. 40 (9): 30–4. PMID 8651827.
- Sampi K, Hattori M (1992). "[Comparative study of cefpiramide + amikacin versus piperacillin + amikacin in granulocytopenic patients: a randomized, prospective study]". Gan to Kagaku Ryoho. 19 (9): 1315–20. PMID 1503486.
Antibacterials active on the cell wall and envelope (J01C-J01D) |
|---|
β-lactams (inhibit synthesis of peptidoglycan layer of bacterial cell wall by binding to and inhibiting PBPs, a group of D-alanyl-D-alanine transpeptidases) | | Penicillins (Penams) | Narrow spectrum | β-lactamase sensitive (1st generation) | |
|---|
β-lactamase resistant (2nd generation) | |
|---|
|
|---|
Extended spectrum | | Aminopenicillins (3rd generation) | |
|---|
| Carboxypenicillins (4th generation) | |
|---|
| Ureidopenicillins (4th generation) | |
|---|
| Other | |
|---|
|
|---|
|
|---|
| Carbapenems / Penems |
- Carbapenems (Ertapenem
- Antipseudomonal (Doripenem
- Imipenem
- Meropenem)
- Biapenem‡
- Panipenem)
- Penems (Faropenem
- Ritipenem§
- Sulopenem)
|
|---|
Cephems Cephalosporins Cephamycins Carbacephems | | 1st generation | |
|---|
| 2nd generation | |
|---|
| 3rd generation | |
|---|
| 4th generation |
- Cefepime
- Cefozopran‡
- Cefpirome
- Cefquinome‡
|
|---|
| 5th generation |
- Ceftaroline fosamil
- Ceftolozane
- Ceftobiprole
|
|---|
| Siderophore | |
|---|
| Veterinary |
- Ceftiofur
- Cefquinome
- Cefovecin
|
|---|
|
|---|
| Monobactams |
- Aztreonam
- Tigemonam‡
- Carumonam‡
- Nocardicin A‡
|
|---|
| β-lactamase inhibitors |
- Penam (Sulbactam
- Tazobactam
- Enmetazobactam)
- Clavam (Clavulanic acid)
- non-β-lactam (Avibactam
- Durlobactam
- Relebactam
- Taniborbactam
- Vaborbactam)
|
|---|
| Combinations |
- Amoxicillin/clavulanic acid#
- Ampicillin/flucloxacillin
- Ampicillin/sulbactam (Sultamicillin)
- Aztreonam/avibactam
- Benzathine benzylpenicillin/procaine benzylpenicillin
- Cefepime/enmetazobactam
- Cefepime/sulbactam
- Cefoperazone/sulbactam
- Ceftazidime/avibactam
- Ceftolozane/tazobactam
- Imipenem/cilastatin#
- Imipenem/cilastatin/relebactam
- Meropenem/vaborbactam
- Panipenem/betamipron
- Piperacillin/tazobactam
- Sulbactam/durlobactam
- Sulopenem/probenecid
- Ticarcillin/clavulanic acid
|
|---|
|
|---|
| Polypeptides | | Lipopeptides |
- Insert into bacterial cell wall causing perforation and depolarization: Daptomycin
- Surfactin
|
|---|
| Other |
- Inhibits PG elongation and crosslinking: Ramoplanin§
|
|---|
|
|---|
| Intracellular |
- Inhibit PG subunit synthesis and transport: NAM synthesis inhibition
- DADAL/AR inhibitors
- bactoprenol inhibitors
|
|---|
| Other |
- Hydrolyze NAM-NAG
- Tyrothricin
- Isoniazid#
- Teixobactin
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|